View Report
March 23, 2026
Measured Result 23.64 mg 94.56% of label claim
British Dragon
British Dragon
Latest Laboratory Result 23.64 mg March 23, 2026 · 94.56% of label claim View
Exemestane 25 mg
Product Information Compound Details
Active Substance Exemestane Irreversible Steroidal Aromatase Inhibitor
25 mgStrength 25 mg/tablet
Package 50 or 100 Tablets
Form Oral Tablets
Drug Class Steroidal Aromatase Inhibitor
Inhibition Type Irreversible
Manufacturer British Dragon
Amount :
50 tabs
100 tabs
Shipping :
International
U.S. Domestic
Out of stock
Product Overview
Exemestane 25 mg by British Dragon
Exemestane 25 mg is an oral steroidal aromatase inhibitor tablet manufactured by British Dragon and dosed at 25 mg per tablet, supplied in packs of 50 or 100 tablets.
Exemestane Oral
Exemestane 25 mg contains exemestane, a potent steroidal aromatase inhibitor that irreversibly binds to the aromatase enzyme (CYP19A1), permanently disabling its ability to convert androgens into estrogens . Unlike non-steroidal inhibitors such as anastrozole and letrozole, exemestane acts as a mechanism-based (suicide) inhibitor, meaning its effects persist until new aromatase enzyme is synthesized .
In clinical medicine, exemestane is FDA-approved for adjuvant treatment of postmenopausal women with estrogen receptor-positive early breast cancer, and for advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy . The standard clinical dose is 25 mg once daily after a meal . In the TEAM trial, exemestane demonstrated efficacy comparable to tamoxifen with a different side effect profile, including higher rates of arthralgia and hot flashes but lower rates of thromboembolic events and vaginal bleeding .
In non-medical bodybuilding and performance-enhancement contexts, exemestane is commonly referenced as an aromatase inhibitor to manage estrogenic side effects during aromatizing anabolic steroid cycles. Its steroidal mechanism and lack of negative feedback on LH/FSH make it distinct from non-steroidal AIs . Such use falls outside approved medical indications and requires careful consideration of individual response.
Key Properties of Exemestane 25 mg
- Irreversible steroidal aromatase inhibitor with suicide mechanism
- FDA-approved for breast cancer treatment in postmenopausal women
- Does not negatively affect LH/FSH feedback at moderate doses
- 25 mg per tablet matches standard clinical dosing
- 50 or 100 tablet pack sizes support extended research protocols
Product Profile
Exemestane Profile
Exemestane is a steroidal aromatase inhibitor that irreversibly binds to the aromatase enzyme, producing sustained estrogen suppression until new enzyme is synthesized .
Steroidal Aromatase Inhibitor
Exemestane is a 6-methylenandrosta-1,4-diene-3,17-dione derivative that acts as a mechanism-based inhibitor of aromatase. It binds irreversibly to the enzyme's substrate-binding site, permanently inactivating it. Because the body must synthesize new aromatase enzyme to restore estrogen production, exemestane's effects persist even after the drug is cleared from circulation .
This mechanism distinguishes exemestane from non-steroidal AIs such as anastrozole and letrozole, which reversibly bind to the enzyme and whose effects diminish as drug concentrations decline. The clinical significance of this difference lies in the potential for prolonged estrogen suppression with exemestane, which may be desirable or undesirable depending on the context .
Exemestane has a terminal elimination half-life of approximately 24 hours, supporting once-daily dosing. Steady-state concentrations are reached within 7 days. The drug is extensively metabolized by CYP3A4 and aldoketoreductases, with less than 1% of the dose excreted unchanged in urine .
Clinical Status
FDA-Approved for Breast Cancer — Not for Research Use
Exemestane is FDA-approved for specific breast cancer indications in postmenopausal women . Products marketed for research purposes are not approved for human use, and non-medical use falls outside approved indications.
Exemestane 25 mg vs Other British Dragon Preparations
British Dragon offers several ancillary compounds used in non-medical bodybuilding contexts. Anastrozole is a non-steroidal AI with reversible binding, while Letrobol contains letrozole, another non-steroidal AI. For post-cycle therapy, Clomiphene and Tamoxifen are commonly referenced for restoring endogenous testosterone production.
Exemestane's distinguishing characteristic among these compounds is its steroidal, irreversible mechanism, which may provide more sustained estrogen suppression and does not negatively affect LH/FSH feedback at moderate doses .
Laboratory Testing
Exemestane 25 mg Lab Reports
Published laboratory reports for Exemestane 25 mg are shown below with the test date, measured result and percentage of the product's 25 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
Dosage & Usage
Exemestane 25 mg Dosage & Usage
The information below is provided for educational reference only. Exemestane is a prescription medication; medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In clinical practice for breast cancer, the standard exemestane dose is 25 mg taken once daily after a meal . In non-medical bodybuilding contexts, exemestane is commonly referenced at lower doses for managing estrogenic side effects, typically 12.5 mg every other day or 6.25–12.5 mg daily, though such use falls outside approved indications and requires careful individual assessment.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Clinical (breast cancer) | 25 mg | Once daily after a meal |
| Non-medical AI management (conservative) | 6.25–12.5 mg | Every other day or daily |
| Non-medical AI management (standard) | 12.5–25 mg | Daily or every other day |
These non-medical ranges represent community-reported practices and are not derived from controlled clinical trials for performance enhancement. Individual response to aromatase inhibition varies, and excessive estrogen suppression carries risks including joint discomfort, adverse lipid changes, and bone density reduction .
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, exemestane is used alongside aromatizing anabolic steroids such as testosterone or Methanabol. The goal is to mitigate estrogenic side effects including water retention, gynecomastia, and elevated blood pressure while maintaining the anabolic benefits of the cycle compounds.
Exemestane should not be stacked with tamoxifen in clinical settings, as the combination may lower exemestane blood levels . In non-medical contexts, bloodwork including estradiol, lipid profile, and liver function is commonly referenced to guide AI dosing.
Managing Side Effects
The most common adverse effects reported with exemestane in clinical trials include hot flashes (incidence 20–25%), arthralgia (15–20%), fatigue, nausea, and increased sweating . In the TEAM trial, exemestane was associated with higher rates of arthralgia and hot flashes compared to tamoxifen, but lower rates of thromboembolic events and vaginal bleeding .
Exemestane lowers estrogen levels, which may lead to loss of bone mineral content and increased fracture risk. Cholesterol elevations have also been reported . In non-medical contexts, excessive estrogen suppression can cause joint dryness, mood changes, and sexual dysfunction, which may be managed by adjusting dosage frequency based on individual response.
Important
Individual Response Varies
Exemestane has approved dosing for specific medical indications. Any information about non-medical use is derived from user-reported practices and is not validated by controlled clinical research. This information does not constitute medical advice.
Safety & Information
Exemestane Safety Information
Exemestane is a prescription medication with known risks that require clinical oversight. It is contraindicated in premenopausal women and during pregnancy .
Important Safety Information
Exemestane is contraindicated in women who are or may become pregnant and in premenopausal women, as it may cause fetal harm and offers no clinical benefit in this population . It is also contraindicated in patients with hypersensitivity to exemestane or any excipients .
Exemestane should not be used in combination with tamoxifen, as the combination may lower exemestane blood levels and reduce its efficacy .
Important
Non-Medical Use
Non-medical use of exemestane falls outside approved indications. Product purity does not establish that non-medical use is safe or appropriate for an individual. Estrogen suppression carries risks that may not be apparent without clinical monitoring.
Potential Adverse Effects
Common adverse reactions (incidence ≥10%) in women taking exemestane include hot flashes, arthralgia, fatigue, nausea, increased sweating, and hypertension . In the TEAM trial, exemestane was associated with higher rates of arthralgia (20% vs 15%) and hot flashes (25% vs 20%) compared to tamoxifen, but lower rates of thromboembolic events (1.5% vs 2.5%) and vaginal bleeding (3% vs 6%) .
Exemestane lowers estrogen levels, which may lead to decreased bone mineral density and increased fracture risk. Cholesterol elevations have also been reported . In clinical trials, exemestane was associated with a higher incidence of osteoporosis and fractures compared to tamoxifen .
Serious adverse reactions reported post-marketing include hepatitis, cholestatic hepatitis, and skin reactions including urticaria and angioedema .
Conditions Requiring Medical Evaluation
Exemestane is not appropriate for everyone. Contraindications include pregnancy, premenopausal status, and hypersensitivity to the drug . Caution is advised in patients with pre-existing osteoporosis, high cholesterol, or hepatic impairment .
Patients should inform their healthcare provider of any bone thinning or weakness, high cholesterol, or other medical conditions before taking exemestane .
Monitoring During Therapy
Medically supervised exemestane therapy may involve monitoring of bone mineral density, serum cholesterol, and liver function . In clinical settings, the TEAM trial demonstrated the need for bone density monitoring in patients receiving exemestane .
Product Care
Storage & Handling
Store tablets in a cool, dry place in the original packaging. Keep out of reach of children. Inspect tablets before use and do not use if they appear damaged or compromised.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Exemestane 25 mg is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official British Dragon distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Exemestane 25 mg product, use the security code on the packaging and cross-check it on the British Dragon official site. Official British Dragon presentation and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Exemestane 25 mg Storage
Proper storage conditions help preserve tablet stability and overall product integrity throughout shelf life.
Recommended Conditions
Store at controlled room temperature (15–25°C) in a cool, dry place, away from direct light and moisture. Keep tablets in their original blister packaging or container until use to protect from humidity.
Inspect tablets before use and do not use if they appear discolored, cracked, or otherwise compromised. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do inspect before each use
- Don't expose to direct sunlight or moisture
- Don't store in bathroom or humid areas
- Don't use if tablets appear abnormal
Frequently Asked Questions
Exemestane 25 mg FAQ
Answers to common questions about Exemestane 25 mg, the Exemestane compound, and its applications.
What is Exemestane 25 mg used for?
Exemestane 25 mg contains the steroidal aromatase inhibitor exemestane. In clinical medicine, it is approved for treatment of hormone receptor-positive breast cancer in postmenopausal women . In non-medical bodybuilding contexts, it is commonly referenced for managing estrogenic side effects from aromatizing anabolic steroids, though such use falls outside approved indications.
How often should Exemestane 25 mg be taken?
The standard clinical dose is 25 mg taken once daily after a meal for breast cancer treatment . In non-medical contexts, exemestane is commonly referenced at lower doses of 6.25–25 mg daily or every other day. These non-medical practices are not derived from controlled clinical trials for performance enhancement.
Does Exemestane 25 mg require PCT?
Exemestane is an aromatase inhibitor, not an anabolic steroid, and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to exemestane in the context of hormonal recovery. In non-medical settings, PCT protocols typically involve Clomiphene or Tamoxifen rather than exemestane.
What does Exemestane do?
Exemestane is a steroidal aromatase inhibitor that irreversibly binds to the aromatase enzyme (CYP19A1), permanently disabling its ability to convert androgens into estrogens . This mechanism produces sustained estrogen suppression until new enzyme is synthesized. It is distinct from non-steroidal AIs such as anastrozole, which bind reversibly.
How long does Exemestane take to work?
Exemestane has a terminal elimination half-life of approximately 24 hours, and steady-state plasma concentrations are typically reached within 7 days of daily administration . Estrogen suppression begins rapidly after the first dose, though the irreversible mechanism means effects persist even after the drug is cleared from circulation .
Is Exemestane the best aromatase inhibitor?
There is no universally established "best" aromatase inhibitor, and each has distinct characteristics. Exemestane is a steroidal AI with an irreversible mechanism, while anastrozole and letrozole are non-steroidal AIs with reversible binding . In the TEAM trial, exemestane demonstrated efficacy comparable to tamoxifen with a different side effect profile .
What is the difference between Exemestane and Anastrozole?
Exemestane and Anastrozole are both aromatase inhibitors but differ in type. Exemestane is a steroidal, irreversible (suicide) inhibitor, while anastrozole is a non-steroidal, reversible inhibitor. Exemestane's effects persist until new enzyme is synthesized, and it does not negatively affect LH/FSH feedback at moderate doses .
What is the difference between Exemestane and Letrozole?
Exemestane and Letrobol (letrozole) are both aromatase inhibitors. Exemestane is steroidal with an irreversible mechanism, while letrozole is non-steroidal with reversible binding. Letrozole is generally considered more potent at suppressing estrogen, while exemestane's steroidal structure may offer different side effect characteristics.
Is 25 mg of Exemestane a lot?
Exemestane 25 mg is the standard clinical dose for breast cancer treatment in postmenopausal women . In non-medical bodybuilding contexts, 25 mg is often considered a high dose for estrogen management, and lower doses or less frequent administration are commonly referenced to avoid excessive estrogen suppression.
What strength is Exemestane 25 mg?
Exemestane 25 mg is labeled at 25 mg of exemestane per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.
Is Exemestane 25 mg lab tested?
Yes. A published laboratory report dated March 23, 2026 measured Exemestane 25 mg at 23.64 mg, equivalent to 94.56% of its 25 mg label claim. The complete report can be viewed in the Lab Reports tab.
Related Offers
British Dragon Pharmaceuticals
Product Information
Compound Details
Active Substance
Methandienone
Dianabol · 17α-Alkylated Oral Anabolic Steroid
10 / 20 / 50 mg
Strength
10, 20, or 50 mg/tablet
Package
100 Tablets
Form
Oral Tablets
Drug Class
Anabolic-Androgenic Steroid
Estimated Half-Life
Approximately 3–6 Hours
Manufacturer
British Dragon
Lab Tested
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Stanozolol Winstrol · DHT-Derived 17α-Alkylated Oral Anabolic Steroid
10 mgStrength 10 mg/tablet
Package 100 Tablets 1,000 mg Total Labeled Content
Form Oral Tablets
Drug Class Anabolic-Androgenic Steroid
Estimated Half-Life Approximately 9 Hours
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information
Compound Details
Active Substance
Tamoxifen Citrate
Selective Estrogen Receptor Modulator (SERM)
20 mg
Strength
20 mg/tablet
Package
50 or 100 Tablets
1,000 mg or 2,000 mg Total Labeled Content
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Estimated Half-Life
Approximately 5–7 Days
Manufacturer
British Dragon
British Dragon Pharmaceuticals
Product Information
Compound Details
Active Substance
Letrozole
Nonsteroidal Competitive Aromatase Inhibitor
2.5 mg
Strength
2.5 mg/tablet
Package
50 or 100 Tablets
Form
Oral Tablets
Drug Class
Aromatase Inhibitor
Inhibition Type
Reversible / Competitive
Manufacturer
British Dragon